Natera (NASDAQ:NTRA) CFO Sells $188,575.52 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 784 shares of the stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $240.53, for a total value of $188,575.52. Following the completion of the transaction, the chief financial officer directly owned 63,339 shares of the company’s stock, valued at approximately $15,234,929.67. The trade was a 1.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, January 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The stock was sold at an average price of $230.40, for a total transaction of $430,156.80.
• On Wednesday, January 28th, Michael Burkes Brophy sold 2,413 shares of Natera stock. The shares were sold at an average price of $237.56, for a total transaction of $573,232.28.
• On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The stock was sold at an average price of $242.54, for a total transaction of $9,016,424.50.
• On Tuesday, January 20th, Michael Burkes Brophy sold 23,948 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $5,621,553.52.

Natera Stock Down 1.9%

NTRA traded down $4.45 during trading on Thursday, reaching $231.48. The stock had a trading volume of 947,123 shares, compared to its average volume of 1,043,018. The stock has a 50 day moving average of $235.90 and a two-hundred day moving average of $193.29. The firm has a market capitalization of $32.02 billion, a price-to-earnings ratio of -101.08 and a beta of 1.62. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $256.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm’s quarterly revenue was up 34.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.26) EPS. On average, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on NTRA. Citigroup initiated coverage on shares of Natera in a report on Wednesday, January 7th. They issued a “buy” rating and a $300.00 target price on the stock. TD Cowen reaffirmed a “buy” rating on shares of Natera in a report on Wednesday, January 7th. Barclays raised their price objective on Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Morgan Stanley boosted their target price on Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Finally, BTIG Research increased their price target on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research report on Friday, December 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $249.20.

Institutional Investors Weigh In On Natera

A number of large investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC lifted its position in shares of Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after buying an additional 96 shares during the last quarter. NewEdge Advisors LLC boosted its position in Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares during the period. Focus Partners Wealth raised its position in shares of Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after purchasing an additional 474 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Natera in the second quarter worth $298,000. Finally, Signaturefd LLC grew its stake in Natera by 10.0% in the 2nd quarter. Signaturefd LLC now owns 1,620 shares of the medical research company’s stock valued at $274,000 after buying an additional 147 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Key Natera News

Here are the key news stories impacting Natera this week:

• Negative Sentiment: CFO Michael Burkes Brophy sold a total of 5,064 shares across Jan. 27–29 for roughly $1.19M (transactions at ~$240.53, $237.56 and $230.40); his holdings fell by ~3% but he still holds ~59k shares. CFO Form 4
• Negative Sentiment: CEO Steven L. Chapman sold 5,970 shares across Jan. 27–28 for roughly $1.43M (avg ~$237–240); his stake decreased ~1–2% and he still owns ~213k shares. CEO Form 4
• Negative Sentiment: Other insiders (John Fesko and Solomon Moshkevich) also sold multiple tranches (combined ~3,925 shares, ~ $0.94M), each reducing holdings by under 1%. Fesko Form 4 Moshkevich Form 4

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.